Zoetis Inc.
Zoetis Announces Heidi C. Chen's Transition to Consultant Role
Summary
On May 20, 2024, Zoetis Inc. announced that Heidi C. Chen will transition to a non-employee consultant role after her separation from her corporate officer position on July 16, 2024. She will receive a consulting fee of $350,000 and may be eligible for additional severance payments. The transition is detailed in a Letter Agreement attached as Exhibit 10.1 to the filing.
Profitelligence Alerts
Get alerts for ZTS
Be first to know when Zoetis Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Zoetis Inc.
Zoetis Inc. is a global leader in the animal healthcare sector, specializing in the development, manufacture, and commercialization of a diverse range of medicines and vaccines for pets and livestock. Originally part of Pfizer, Zoetis spun off in 2013 and has solidified its position as a key player in the industry. The company's portfolio includes products aimed at veterinarians and livestock producers, supporting health and productivity across various animal species. Zoetis's impact is significant in both the companion animal market, which is driven by increasing pet ownership and rising expenditure on pet care, and the livestock market, which benefits from enhancements in productivity and disease management. Zoetis operates in over 100 countries, continuously investing in research and innovation to address the evolving needs of animal health. Its strategic initiatives and partnerships contribute to building a sustainable future for the animal health industry, bolstering Zoetis’s reputation and relevance in the global market.
Official SEC Documents
Advertisement